This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Neoadjuvant KEYTRUDA® (pembrolizumab) + chemotherapy followed by adjuvant KEYTRUDA monotherapy in patients with triple-negative breast cancer (TNBC)

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.1

 

KEYTRUDA® (pembrolizumab) + chemotherapy for patients with locally recurrent unresectable or metastatic TNBC

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.1

 

KEYTRUDA® in combination with chemotherapy

 

Please refer to Summary of Product Characteristics for full list of AEs and management.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02100 | Date of Preparation: June 2022